文献速递神经肿瘤小儿神经外科与脑积水

儿童低级别胶质瘤放疗后的假性进展

Pseudoprogression in pediatric low-grade glioma after irradiation.
PubMed 文献 · J Neurooncol · 2017-07-27

这项回顾性研究纳入221例21岁及以下接受根治性放疗的颅内低级别胶质瘤患者,评估放疗后假性进展的发生率与管理。62例出现假性进展,10年累积发生率29.0%(95%CI 23.0-35.2),中位发生时间放疗后6.1个月。毛细胞型星形细胞瘤(PA)发生假性进展的比值比为其他组织学的5.4倍(95%CI 2.5-11.4,P<0.0001)。

要点

  • 221例中62例出现假性进展,10年累积发生率29.0%(95%CI 23.0-35.2)
  • 假性进展中位时间放疗后6.1个月,68%仅观察
  • PA患者10年累积发生率42.9%,假性进展与10年EFS和OS改善相关

核心结论

  • 放疗后假性进展常见,尤其在毛细胞型星形细胞瘤患者中,并与生存改善相关。

研究设计与样本

  • 回顾性研究纳入221例21岁及以下接受根治性放疗的颅内低级别胶质瘤患者。

主要发现

  • 62/221例出现假性进展,10年累积发生率29.0%(95%CI 23.0-35.2),中位发生时间放疗后6.1个月。
  • 有症状假性进展接受次全切除11例(18%)、分流/Ommaya储液囊置入7例(11%)、皮质激素2例(3%),其余68%观察。
  • PA患者发生假性进展的比值比为其他组织学的5.4倍(OR 95%CI 2.5-11.4,P<0.0001)。
  • PA患者(n=127)10年累积发生率42.9%;假性进展组10年EFS 84.5% vs 无假性进展组58.5%(P=0.008),OS 98.0% vs 91.2%(P=0.03)。

关键数值与推荐

  • 假性进展定义为连续2至3次MR检查中肿瘤在两个维度上增大≥10%。
  • EFS定义为无真性进展或继发性高级别胶质瘤生存,OS和EFS均从放疗第一天起算。

临床怎么用

  • 了解假性进展的发生率与时间过程可能有助于避免不必要的挽救治疗。
  • 有症状假性进展可接受次全切除、分流/Ommaya储液囊置入或皮质激素处理,其余可观察。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to assess the incidence and management of pseudoprogression after radiation therapy (RT) in patients with pediatric low-grade glioma (LGG). This retrospective review included patients aged 21 years or younger with intracranial LGG treated with curative-intent RT. Pseudoprogression was defined as an increase in tumor size by ≥10% in at least two dimensions between two and three consecutive MR imaging studies. Overall survival (OS) and event-free survival (EFS) were measured from the first day of RT. EFS was defined as survival without true progression or secondary high-grade glioma. Sixty-two of 221 patients developed pseudoprogression, with a 10-year cumulative incidence of 29.0% (95% CI 23.0-35.2). Median time to pseudoprogression was 6.1 months after RT. Symptomatic pseudoprogression was managed with subtotal resection, shunt/Ommaya reservoir placement, or corticosteroids in 11 (18%), 7 (11%), and 2 patients (3%), respectively. The remaining tumors were observed (68%). Patients with pilocytic astrocytoma (PA) had 5.4-fold greater odds of developing pseudoprogression relative to tumors of other histology (odds ratio 95% CI 2.5-11.4, P < 0.0001). Among patients with PA (n = 127), the 10-year cumulative incidence of pseudoprogression was 42.9%. In this group, pseudoprogression was associated with improved 10-year EFS (84.5% vs. 58.5%, P = 0.008) and OS (98.0% vs. 91.2%, P = 0.03). Pseudoprogression after irradiation was common, especially in patients with pilocytic astrocytoma, and was associated with improved survival. Knowledge of the incidence and temporal course of pseudoprogression may help avoid unnecessary salvage therapy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Tsang DS, Murphy ES, Lucas JT, et al. Pseudoprogression in pediatric low-grade glioma after irradiation. J Neurooncol. 2017. PMID: 28752498. doi:10.1007/s11060-017-2583-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。